Related Experiment Video

Updated: May 2, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

27.4K

The Nobori biolimus-eluting stent: update of available evidence

Raffaele Piccolo1, Annamaria Nicolino, Gian Battista Danzi

  • 1Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.

Expert Review of Medical Devices
|March 4, 2014
PubMed

Insights

The Nobori biolimus-eluting stent (BES), a biodegradable option, offers a promising alternative to first-generation drug-eluting stents (DES) by potentially reducing long-term thrombotic event risks. This review synthesizes data from various studies on its efficacy and safety.

Area of Science:

  • Cardiovascular Medicine
  • Biomaterials Science
  • Interventional Cardiology

Background:

  • First-generation drug-eluting stents (DES) reduced repeat revascularization but increased long-term thrombotic risks.
  • The Nobori biolimus-eluting stent (BES) utilizes a biodegradable poly-lactic acid polymer, representing a second-generation DES.
  • The Nobori BES is the most studied biodegradable DES, with multiple comparative trials.

Purpose of the Study:

  • To review and synthesize available data on the Nobori biolimus-eluting stent (BES).
  • To evaluate the safety and efficacy of the Nobori BES compared to other DES.
  • To assess the role of biodegradable polymer DES in percutaneous coronary intervention.

Main Methods:

  • Systematic review of pharmacokinetic studies.
  • Analysis of observational studies.
  • Evaluation of randomized clinical trials comparing Nobori BES with other DES.

Main Results:

  • Data synthesis from diverse study types provides a comprehensive overview of Nobori BES performance.
  • Comparative trials inform the clinical positioning of biodegradable polymer DES.
  • Pharmacokinetic data may elucidate the stent's drug release profile and biological interaction.

Conclusions:

  • The Nobori BES represents a significant advancement in DES technology with a biodegradable polymer.
  • Evidence from multiple trials supports its investigation and potential clinical utility.
  • Further analysis of long-term outcomes is crucial for establishing its definitive role in interventional cardiology.

More Related Videos

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

11.0K
Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

9.3K

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
535
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K